Get started
Avidity Biosciences, Inc.Avidity Biosciences, Inc.Avidity Biosciences, Inc.

Avidity Biosciences, Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Options

RNA trade ideas

Avidity Biosciences (RNA) Analysis RNA Therapeutics Leadership: Avidity Biosciences NASDAQ:RNA is at the forefront of RNA therapeutics with its innovative antibody-oligonucleotide conjugates (AOCs). Its lead candidate, Del-desiran (AOC 1001), targeting myotonic dystrophy type 1, is on the verge of a pivotal trial. Approval could significantly boost earnings. Strategic Partnership: Avidity's partnership with Bristol Myers Squibb, valued at up to $2.3 billion, focuses on cardiovascular targets, expanding their collaboration and enhancing the potential for groundbreaking treatments. Clinical Milestones: A major clinical update for AOC 1001 is expected by mid-2025. Success in this trial could validate Avidity’s platform and unlock significant value. Additionally, the company is developing treatments for Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Investment Outlook: Bullish Outlook: We are bullish on RNA above the $24.00-$24.50 range. Upside Potential: With a target set at $34.00-$35.00, Avidity's innovative approach and diversified pipeline present significant growth potential. 📊🧬 Stay informed about Avidity Biosciences for promising investment opportunities! #RNA #Therapeutics 📈🔍
NASDAQ:RNALong
by Richtv_official
RNA is giving a GREAT IPO LONG opportunity today IPO intraday trading strategy idea Avidity Biosciences is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. The share price is rising and gonna continue this trend today. The demand for shares of the company still looks higher than the supply. These and other conditions can cause a rise in the share price today. So I opened a long position from $28,4; take-profit — $38,12 stop-loss — $25,16 Do not view this idea as a recommendation for trading or investing. It is published only to introduce my own vision. Always do your own analysis before making deals. When you use any materials, do not rely on blind trust. You should remember that isolated deals do not give systematic profit, so trade/invest using a developed strategy. If you like my content, you can subscribe to the news and receive my fresh ideas. Thanks for being with me!
NASDAQ:RNALong
by KozakHlib
1